Dr. Reddy's Laboratories Ltd.

BSE: DRREDDY500124ISIN INE089A01031

Healthcare
Pharmaceuticals
BSE 100

Share price

₹1,372.00+2.00 (+0.15%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

28 Oct 2024 · Split 5:1 (₹5 → ₹1)

52W high: ₹1,414.40
52W low: ₹1,080.05
Off 52W high: -3.00%
1M return: +13.58%
3M return: +16.87%
6M return: +4.69%
1Y return: +14.26%
20D avg volume: 1,13,801
50 DMA: ₹1,216.70
200 DMA: ₹1,247.46

Key ratios Consolidated

Market cap: ₹1,14,513 Cr
Current price: ₹1,372.00
52W high / low: ₹1,414.40 / ₹1,080.05
Face value: ₹1.00
P/E: 41.50
P/B: 2.95
EPS (TTM): ₹33.06
Book value / share: ₹464.75
ROE: —
ROCE: 13.90%
Operating margin: —
Net margin: —
Debt / equity: 0.16
Net debt: ₹4,757 Cr
Interest cover: 15.39
Dividend yield: 0.58%
Dividend / share (TTM): ₹8.00
Payout: 24.20%
Cash conversion cycle: 159.6 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	8,698	8,100	7,546	8,753	8,828	8,572	8,528	8,381	8,038	7,696	7,114	7,237
	156.20	354.70	475.40	268.80	323.90	290.30	522.10	150.20	307.50	187.20	197.50	216.20
	8,854	8,454	8,022	9,022	9,152	8,862	9,050	8,531	8,346	7,883	7,311	7,453
	7,619	7,902	7,827	7,481	7,414	6,958	7,051	6,661	6,434	6,007	5,710	5,627
	1,661	1,654	1,199	1,826	1,441	2,036	1,716	1,453	1,287	1,227	1,096	1,141
	1,538	1,974	1,658	1,542	1,746	1,216	1,128	1,051	1,283	1,380	1,176	1,208
	1,612	1,652	1,447	1,588	1,452	1,504	1,401	1,366	1,399	1,414	1,284	1,276
	124.80	125.50	105.70	94.40	90.70	83.00	65.60	81.70	75.70	59.80	59.30	39.40
	526.70	536.60	557.10	521.00	504.60	476.10	454.70	471.40	397.00	380.60	367.70	373.50
	2,187	2,203	2,504	2,182	2,243	2,088	2,280	2,161	2,103	—	1,924	—
	1,235	552.50	195.10	1,541	1,738	1,905	2,000	1,870	1,911	1,877	1,602	1,826
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	1,235	552.50	195.10	1,541	1,738	1,905	2,000	1,870	1,911	1,877	1,602	1,826
	314.40	117.70	-21.60	353.60	408.00	495.10	418.50	470.10	575.50	490.20	295.40	448.20
	913.20	435.60	221.30	1,190	1,337	1,410	1,587	1,404	1,342	1,392	1,310	1,381
	11.10	5.33	2.65	14.53	16.18	17.04	19.12	16.97	15.08	83.61	78.66	82.94
Key metrics
	1,887	1,215	857.90	2,156	2,334	2,464	2,520	2,423	2,384	2,317	2,029	2,239
	21.70%	15.00%	11.40%	24.60%	26.40%	28.70%	29.50%	28.90%	29.70%	30.10%	28.50%	30.90%
	10.50%	5.40%	2.90%	13.60%	15.10%	16.40%	18.60%	16.80%	16.70%	18.10%	18.40%	19.10%
	3.20%	—	0.70%	—	4.70%	—	5.70%	—	—	—	—	—
	-1.50%	-5.50%	-11.50%	4.40%	9.80%	11.40%	19.90%	15.80%	—	—	—	—
	-31.70%	-69.10%	-86.10%	-15.30%	-0.40%	1.30%	21.10%	1.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	33,097	33,700	32,644	28,011	24,670	21,545	19,048	17,517	15,448	14,281	14,196
	1,255	1,358	1,097	894.30	1,056	484.40	291.40	620.60	337.50	155.20	171.50
	34,352	35,059	33,741	28,905	25,725	22,030	19,339	18,138	15,786	14,436	14,368
	30,829	29,679	26,083	21,719	19,714	19,038	16,503	16,308	13,494	13,086	12,814
	6,339	6,501	5,684	4,490	4,220	4,312	4,296	2,985	2,889	2,631	2,193
	6,711	6,162	4,841	4,399	3,367	3,484	2,574	2,546	1,881	1,450	—
	6,299	5,991	5,580	5,030	4,647	3,886	3,630	3,380	3,356	3,215	3,107
	450.40	373.80	282.90	171.10	142.80	95.80	97.00	98.30	88.90	78.80	63.40
	2,141	2,059	1,704	1,470	1,250	1,165	1,229	1,163	1,135	—	1,027
	9,077	9,017	8,537	6,839	—	—	—	—	—	—	3,879
	3,524	5,379	7,658	7,186	6,012	2,991	2,836	1,830	2,292	1,350	1,554
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	3,524	5,379	7,658	7,186	6,012	2,991	2,836	1,830	2,292	1,350	1,554
	764.10	1,235	1,954	1,623	1,541	878.90	931.90	140.30	385.80	438.00	296.50
	2,760	4,158	5,725	5,578	4,507	2,182	1,952	2,026	1,950	912.40	1,257
	33.61	50.41	67.89	335.22	271.47	131.57	117.67	122.22	117.53	—	77.53
Key metrics
	6,116	7,812	9,644	8,827	7,404	4,252	4,161	3,091	3,516	1,429	2,644
	18.48%	23.20%	29.50%	31.50%	30.00%	19.70%	21.80%	17.60%	22.80%	10.00%	18.60%
	8.34%	12.30%	17.50%	19.90%	18.30%	10.10%	10.20%	11.60%	12.60%	6.40%	8.90%
	—	13.90%	21.80%	—	—	—	—	—	—	—	—
	-3.53%	3.20%	16.50%	13.50%	14.50%	13.10%	8.70%	13.40%	8.20%	0.60%	—
	-51.90%	-27.40%	2.60%	23.80%	106.50%	11.80%	-3.70%	3.90%	113.70%	-27.40%	—
	—	3,343	1,892	—	—	—	—	—	—	—	—
	—	1.36	0.81	—	—	—	—	—	—	—	—
	—	0.16	0.12	—	—	—	—	—	—	—	—
	—	4,757	2,719	—	—	—	—	—	—	—	—
	—	159.6	151.0	—	—	—	—	—	—	—	—
Balance sheet
	—	58,123	49,427	—	—	—	—	—	—	—	—
	—	30,179	25,018	—	—	—	—	—	—	—	—
	—	1,537	1,465	—	—	—	—	—	—	—	—
	—	10,123	9,042	—	—	—	—	—	—	—	—
	—	7,653	7,108	—	—	—	—	—	—	—	—
	—	2,990	2,707	—	—	—	—	—	—	—	—
	—	10,078	7,298	—	—	—	—	—	—	—	—
	—	3,038	2,648	—	—	—	—	—	—	—	—
	—	16,747	13,034	—	—	—	—	—	—	—	—
	—	6,294	4,184	—	—	—	—	—	—	—	—
	—	6,294	3,804	—	—	—	—	—	—	—	—
	—	0.00	380.00	—	—	—	—	—	—	—	—
	—	38,231	33,927	—	—	—	—	—	—	—	—
Cash flow
	—	5,674	4,643	—	—	—	—	—	—	—	—
	—	-6,549	-5,102	—	—	—	—	—	—	—	—
	—	829.00	1,186	—	—	—	—	—	—	—	—
	—	2,331	2,750	—	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	5,573	5,137	3,822	4,283	4,619	7,810	5,563	5,015	6,696	5,841	5,105	4,103
	217.30	440.40	567.20	360.30	364.20	398.30	414.40	235.40	207.60	217.80	212.70	227.60
	5,790	5,577	4,389	4,643	4,983	8,208	5,977	5,250	6,904	6,059	5,318	4,331
	4,889	5,080	4,695	4,539	4,466	4,272	4,416	4,131	4,263	4,145	3,978	3,699
	1,284	1,306	1,121	1,067	1,009	1,136	942.60	1,012	934.30	911.10	907.70	818.70
	722.60	902.20	479.00	769.20	723.80	663.80	534.70	508.40	656.50	740.30	546.30	556.90
	957.40	967.00	834.50	960.20	867.90	887.30	797.10	794.40	840.10	855.90	779.50	782.30
	77.00	73.10	54.30	41.40	33.40	19.20	31.10	43.30	28.40	7.10	5.90	5.60
	333.70	317.70	318.50	314.30	294.80	279.80	264.50	265.10	260.00	249.80	246.20	246.40
	1,521	1,566	1,771	1,518	1,540	1,499	1,763	1,545	1,637	—	1,519	—
	901.30	497.00	-305.50	104.20	516.30	3,936	1,562	1,119	2,641	1,914	1,339	631.90
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	901.30	497.00	-305.50	104.20	516.30	3,936	1,562	1,119	2,641	1,914	1,339	631.90
	205.50	92.30	-86.10	13.60	129.00	975.10	361.10	270.00	758.70	496.70	304.40	156.70
	695.80	404.70	-219.40	90.60	387.30	2,961	1,201	849.40	1,882	1,417	1,035	475.20
	8.35	4.86	-2.63	1.09	4.65	35.59	14.41	10.20	22.60	85.10	62.14	28.55
Key metrics
	1,312	887.80	67.30	459.90	844.50	4,235	1,857	1,428	2,929	2,171	1,591	883.90
	23.50%	17.30%	1.80%	10.70%	18.30%	54.20%	33.40%	28.50%	43.70%	37.20%	31.20%	21.50%
	12.50%	7.90%	-5.70%	2.10%	8.40%	37.90%	21.60%	16.90%	28.10%	24.30%	20.30%	11.60%
	3.00%	—	-0.80%	—	1.70%	—	5.40%	—	—	—	—	—
	20.70%	-34.20%	-31.30%	-14.60%	-31.00%	33.70%	9.00%	22.20%	—	—	—	—
	79.70%	-86.30%	-118.30%	-89.30%	-79.40%	108.90%	16.00%	78.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	18,814	20,533	23,115	19,484	16,962	14,405	13,349	11,850	10,626	9,359	9,720
	1,585	1,690	1,003	862.30	591.30	482.00	801.10	743.20	238.40	204.00	591.20
	20,399	22,222	24,119	20,346	17,554	14,887	14,150	12,594	10,864	9,563	10,311
	19,202	17,971	16,883	14,555	13,688	12,663	11,094	9,818	9,163	8,866	8,766
	4,778	4,332	3,800	3,292	3,161	3,378	3,266	2,556	2,103	2,011	1,818
	2,873	2,636	2,440	1,987	1,779	2,057	1,252	1,117	868.60	671.60	671.50
	3,719	3,550	3,288	3,086	2,833	2,435	2,270	2,030	1,932	1,843	1,803
	245.80	148.30	109.90	21.80	16.90	38.00	46.70	47.80	56.80	62.80	57.20
	1,284	1,207	1,039	975.60	923.20	814.30	835.00	789.20	780.60	774.10	—
	6,377	6,328	6,380	5,406	—	—	—	—	—	—	—
	1,197	4,251	7,236	5,791	3,866	2,224	3,056	2,776	1,701	697.00	1,544
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	1,197	4,251	7,236	5,791	3,866	2,224	3,056	2,776	1,701	697.00	1,544
	225.30	1,032	1,886	1,449	1,253	600.60	869.80	161.90	423.40	130.10	160.40
	971.70	3,220	5,349	4,342	2,613	1,623	2,186	2,938	1,277	566.90	1,384
	11.67	38.68	64.22	260.95	157.37	97.85	131.84	177.23	76.98	—	83.05
Key metrics
	2,727	5,607	8,385	6,789	4,806	3,076	3,938	3,613	2,538	1,534	1,602
	14.49%	27.30%	36.30%	34.80%	28.30%	21.40%	29.50%	30.50%	23.90%	16.40%	16.50%
	5.16%	15.70%	23.10%	22.30%	15.40%	11.30%	16.40%	24.80%	12.00%	6.10%	14.20%
	—	13.60%	24.80%	—	—	—	—	—	—	—	—
	-18.22%	-11.20%	18.60%	14.90%	17.80%	7.90%	12.60%	11.50%	13.50%	-3.70%	—
	-82.00%	-39.80%	23.20%	66.20%	61.00%	-25.80%	-25.60%	130.00%	125.30%	-59.00%	—
	—	2,611	1,886	—	—	—	—	—	—	—	—
	—	1.45	0.79	—	—	—	—	—	—	—	—
	—	0.17	0.12	—	—	—	—	—	—	—	—
	—	5,082	3,066	—	—	—	—	—	—	—	—
	—	127.5	134.9	—	—	—	—	—	—	—	—
Balance sheet
	—	43,602	38,291	—	—	—	—	—	—	—	—
	—	18,523	16,503	—	—	—	—	—	—	—	—
	—	337.50	319.70	—	—	—	—	—	—	—	—
	—	4,119	5,959	—	—	—	—	—	—	—	—
	—	4,956	4,576	—	—	—	—	—	—	—	—
	—	2,219	1,964	—	—	—	—	—	—	—	—
	—	7,753	5,865	—	—	—	—	—	—	—	—
	—	1,904	1,993	—	—	—	—	—	—	—	—
	—	11,142	8,652	—	—	—	—	—	—	—	—
	—	5,419	3,386	—	—	—	—	—	—	—	—
	—	5,419	3,386	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	31,366	28,857	—	—	—	—	—	—	—	—
Cash flow
	—	4,660	4,225	—	—	—	—	—	—	—	—
	—	-5,785	-5,698	—	—	—	—	—	—	—	—
	—	1,117	1,591	—	—	—	—	—	—	—	—
	—	2,049	2,339	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.57%
Sales CAGR 5Y: +8.99%
Profit CAGR 3Y: +7.21%
Profit CAGR 5Y: +8.05%
Sales YoY (TTM): -18.22%
Profit YoY (TTM): -82.00%

Consolidated

Sales CAGR 3Y: +10.96%
Sales CAGR 5Y: +12.09%
Profit CAGR 3Y: -2.66%
Profit CAGR 5Y: +16.33%
Sales YoY (TTM): -3.53%
Profit YoY (TTM): -51.90%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 26.62%

Quarter	September 2026	June 2026
Promoter %	26.62%	26.62%

Holder	Type	Holding	Previous	Change
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND	Public	12.14%	12.16%	-0.02%
GVP Family Trust	Promoter Group	11.51%	11.51%	0.00%
J P Morgan Chase Bank NA	Public	11.10%	11.41%	-0.31%
VSD Family Trust	Promoter Group	9.06%	9.06%	0.00%
ISIF EQUITY EX-TOP 100 LONG-SHORT FUND	Public	5.76%	—	—
KALLAM SATISH REDDY HUF	Promoter	3.31%	3.31%	0.00%
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2	Public	2.93%	3.15%	-0.22%
NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND	Public	1.58%	1.88%	-0.30%
GUNUPATI VENKATESWARA PRASAD HUF	Promoter	1.52%	1.52%	0.00%
PARAG PARIKH FLEXI CAP FUND	Public	1.46%	1.76%	-0.30%
SATISH REDDY KALLAM	Promoter	1.21%	1.21%	0.00%
SBI NIFTY INDEX FUND	Public	1.21%	1.43%	-0.22%
ANURADHA GUNUPATI	Promoter	0.01%	0.01%	0.00%
GUNUPATI MALLIKA REDDY	Promoter	0.00%	0.00%	0.00%
Dakshin Builders	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Allotment of Employee Stock options4 Nov 2026 · Company Update / Allotment of ESOP / ESPS
Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20154 Nov 2026 · Company Update / General
The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) ....3 Nov 2026 · Company Update / Clarification
Transcript of Earnings call29 Oct 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201528 Oct 2026 · Company Update / General
Copies of newspaper advertisement24 Oct 2026 · Company Update / Newspaper Publication
Audio Recording of the Earnings call conducted on October 23, 202624 Oct 2026 · Company Update / Analyst / Investor Meet
Limited Review report of the Statutory Auditors on the Unaudited Financial results for the quarter and half year ended September 30, 2026 with UDIN23 Oct 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201523 Oct 2026 · Company Update / Change in Management
Outcome of Board meeting held on October 23, 202623 Oct 2026 · Board Meeting / Outcome of Board Meeting
Copy of Investor Presentation23 Oct 2026 · Company Update / General
Unaudited Financial results for quarter and half year ended September 30, 202623 Oct 2026 · Result / Financial Results
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201521 Oct 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514 Oct 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20158 Oct 2026 · Company Update / General
Intimation of Earnings call7 Oct 2026 · Company Update / Press Release / Media Release
Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 20187 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20153 Oct 2026 · Company Update / General
Closure of Trading window22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....22 Sep 2026 · Board Meeting / Board Meeting
Intimation of analyst meet21 Sep 2026 · Company Update / Analyst / Investor Meet
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201518 Sep 2026 · Company Update / Press Release / Media Release
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201518 Sep 2026 · Company Update / General
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....17 Sep 2026 · Company Update / Clarification
Copies of newspaper publication16 Sep 2026 · Company Update / Newspaper Publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201511 Sep 2026 · Company Update / General
Allotment of Employee Stock options10 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Analyst meet10 Sep 2026 · Company Update / Analyst / Investor Meet
Allotment of Employee Stock options26 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Copies of newspaper publication20 Aug 2026 · Company Update / Newspaper Publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201514 Aug 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund14 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Change in Senior Management Personnel13 Aug 2026 · Company Update / Change in Management
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 21057 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 21057 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 20157 Aug 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Press Release1 Aug 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201529 Jul 2026 · Company Update / General
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 201529 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 8.0000	10 Jul 2026	10 Jul 2026	—
Final Dividend - Rs. - 8.0000	10 Jul 2025	10 Jul 2025	—
Stock Split From Rs.5/- to Rs.1/-	28 Oct 2024	28 Oct 2024	—
Final Dividend - Rs. - 40.0000	16 Jul 2024	—	—

Board meetings

23 Oct 2026 Board Meeting - Financial Results
22 Jul 2026 Board Meeting - Financial Results